Back to Search
Start Over
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
- Source :
- The Lancet Respiratory Medicine; August 2024, Vol. 12 Issue: 8 p589-598, 10p
- Publication Year :
- 2024
-
Abstract
- Garsorasib (D-1553; InventisBio, Shangai, China), a potent KRASG12Cinhibitor, has shown promising antitumour activity in patients with KRASG12C-mutated (ie, Gly12Cys) non-small-cell lung cancer (NSCLC) in a phase 1 study. We report results from a phase 2 study conducted to evaluate the efficacy and safety of garsorasib in patients with locally advanced or metastatic KRASG12C-mutated NSCLC.
Details
- Language :
- English
- ISSN :
- 22132600 and 22132619
- Volume :
- 12
- Issue :
- 8
- Database :
- Supplemental Index
- Journal :
- The Lancet Respiratory Medicine
- Publication Type :
- Periodical
- Accession number :
- ejs66627989
- Full Text :
- https://doi.org/10.1016/S2213-2600(24)00110-3